Israel's MediWound beats Q2 revenue estimates, reaffirms 2026 guidance

Mediwound

13/08/2026 12:14

Overview
Israel biotech's Q2 revenue fell but beat analyst expectations
Gross profit margin declined due to one-time facility scale-up impact
Company reaffirmed full-year 2026 revenue guidance of $24–26 mln

Outlook
MediWound reaffirms 2026 revenue guidance of $24–26 mln
Company expects to begin recognizing revenue from Vericel agreement in H2 2026
Commercial supply from expanded NexoBrid facility expected in H2 2027, pending approval

Result Drivers
BARDA REVENUE TIMING - Co said lower Q2 revenue and gross profit reflected timing of BARDA-funded development revenue
R&D INVESTMENT - Increased research and development expenses were driven by investment in EscharEx Phase III VALUE trial
NEXOBRID ADOPTION - Vericel reported record quarterly revenue and hospital unit sales for NexoBrid, reflecting continued adoption in U.S. burn care market

Company press release: ID:nGNXbHt3p2

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$3.10 mln
$2.59 mln (6 Analysts)
Q2 Loss Per Share
 
$0.57
 
Q2 Net Loss
 
$7.40 mln
 
Q2 Adjusted EBITDA
Beat
-$8.30 mln
-$8.74 mln (2 Analysts)
Q2 Gross Profit
 
$337,000
 
Q2 Operating Income
 
-$9.50 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mediwound Ltd is $31.00, about 122.9% above its August 12 closing price of $13.91

Reuters Recommended Reads
Aug 12 - Israel's Kamada Q2 revenue beats estimates on KEDRAB growth
Aug 12 - Israel's Protalix Q2 revenue rises on Elfabrio sales, reiterates 2026 outlook
Aug 12 - Israel's IceCure Medical H1 revenue rises on higher system, probe sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)